Gut microbiota as a potential predictor of therapeutic response in adults with Crohn’s disease: A systematic review

Table 3 Bacterial taxonomy at baseline before starting treatment and prediction of response to therapy

Ref.	Bacterial taxonomy
Ananthakrishnan et al[57], 2017	Treatment responders had higher abundance of Burkholderiales species and Roseburia inulinivorans and butyrate producers than non-responders. Microbial dysbiosis index showed no significant difference between the two groups
Doherty et al[9], 2018	Treatment responders had higher abundance of Bacteroides (P = 0.022) and Faecalibacterium (P = 0.003) than non-responders
Park et al[64], 2022	Stool samples: Actinobacteria, Dorea, Agathobaculum, and Blautia levels were higher and Proteobacteria, Enterobacteriaceae, Odoribacter and Ruminococcus gnavus were lower in anti-TNF-α responders. Saliva samples: Levels of Abiotrophia defective-species, and FJ976422_s-species were higher and Ralstonia were lower in responders than in non-responders
Yilmaz et al[68], 2019	Higher abundance of Bifidobacterium, Collinsella, Lachnospira, Lachnospiraceae, Roseburia, Eggerthella taxa and lower abundance of Phascolarctobacterium noted in treatment responders than non-responders to anti TNF therapy. No differences noted between the responders and non-responders to steroid treatment
Guo et al[62], 2024	Lower abundance of Ruminococcus, Lachnoclostridium, Akkermansia in bacterial community and lower abundance of Asterotremella and Wallemia in fungal community noted in non-responder group compared to responders
Dovrolis et al[60], 2020	Parvimonas, Hungatella, Roseburia, Ruminococcus and Stenotrophomonas were associated with responders, and Negativibacillus, Faecalibacterium, Eubacterium_hallii_group, Blautia, Ruminococcus_gnavus_group were associated with non responders
Lee et al[63], 2021	Clostridium citronae, Agathobaculum butyriciproducens associated with remission after anti-cytokine therapy, B stercoris with anti-integrin therapy and B. caccae and B. ovatus with both types of therapies
Caenepeel et al[69], 2024	Enterotype Bacteroides 2 was negatively associated with remission after treatment with Vedolizumab. No association was found with Ustekinumab or anti-TNF agents
Sanchis-Artero et al[66], 2021	Significant difference in Faecalibacterium prausnitzii/Escherichia coli (F/E) ratio noted between responders and non-responders (P < 0.01)
Effenberger et al[61], 2021	No significant difference at genus level between responders and non-responders
Ding et al[59], 2020	No significant difference in micorbial profiles of responders and non-responders
Ribaldone et al[65], 2019	No significant difference in concentration of all taxa between responder and non-responder

TNF: Tumour necrosis factor.